273 related articles for article (PubMed ID: 28098219)
1. Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson's disease.
Liu HF; Ho PW; Leung GC; Lam CS; Pang SY; Li L; Kung MH; Ramsden DB; Ho SL
Sci Rep; 2017 Jan; 7():40887. PubMed ID: 28098219
[TBL] [Abstract][Full Text] [Related]
2. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
[TBL] [Abstract][Full Text] [Related]
3. Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease.
Tozzi A; Tantucci M; Marchi S; Mazzocchetti P; Morari M; Pinton P; Mancini A; Calabresi P
Cell Death Dis; 2018 Feb; 9(2):204. PubMed ID: 29434188
[TBL] [Abstract][Full Text] [Related]
4. LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
Sloan M; Alegre-Abarrategui J; Potgieter D; Kaufmann AK; Exley R; Deltheil T; Threlfell S; Connor-Robson N; Brimblecombe K; Wallings R; Cioroch M; Bannerman DM; Bolam JP; Magill PJ; Cragg SJ; Dodson PD; Wade-Martins R
Hum Mol Genet; 2016 Mar; 25(5):951-63. PubMed ID: 26744332
[TBL] [Abstract][Full Text] [Related]
5. In vivo overexpression of synaptogyrin-3 promotes striatal synaptic dopamine uptake in LRRK2
Ho PW; Li L; Liu HF; Choi ZY; Chang EES; Pang SY; Malki Y; Leung CT; Kung MH; Ramsden DB; Ho SL
Brain Behav; 2023 Feb; 13(2):e2886. PubMed ID: 36624932
[TBL] [Abstract][Full Text] [Related]
6. Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA).
Ho PW; Leung CT; Liu H; Pang SY; Lam CS; Xian J; Li L; Kung MH; Ramsden DB; Ho SL
Autophagy; 2020 Feb; 16(2):347-370. PubMed ID: 30983487
[TBL] [Abstract][Full Text] [Related]
7. Parkinson's disease-related Leucine-rich repeat kinase 2 modulates nuclear morphology and genomic stability in striatal projection neurons during aging.
Chen X; Xie C; Tian W; Sun L; Zheng W; Hawes S; Chang L; Kung J; Ding J; Chen S; Le W; Cai H
Mol Neurodegener; 2020 Feb; 15(1):12. PubMed ID: 32075681
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial Calcium Dysregulation Contributes to Dendrite Degeneration Mediated by PD/LBD-Associated LRRK2 Mutants.
Verma M; Callio J; Otero PA; Sekler I; Wills ZP; Chu CT
J Neurosci; 2017 Nov; 37(46):11151-11165. PubMed ID: 29038245
[TBL] [Abstract][Full Text] [Related]
9. LRRK2 kinase inhibition protects against Parkinson's disease-associated environmental toxicants.
Ilieva NM; Hoffman EK; Ghalib MA; Greenamyre JT; De Miranda BR
Neurobiol Dis; 2024 Jun; 196():106522. PubMed ID: 38705492
[TBL] [Abstract][Full Text] [Related]
10. Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes.
Mercatelli D; Bolognesi P; Frassineti M; Pisanò CA; Longo F; Shimshek DR; Morari M
Pharmacol Res Perspect; 2019 Jun; 7(3):e00484. PubMed ID: 31149340
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation of amyloid precursor protein by mutant LRRK2 promotes AICD activity and neurotoxicity in Parkinson's disease.
Chen ZC; Zhang W; Chua LL; Chai C; Li R; Lin L; Cao Z; Angeles DC; Stanton LW; Peng JH; Zhou ZD; Lim KL; Zeng L; Tan EK
Sci Signal; 2017 Jul; 10(488):. PubMed ID: 28720718
[TBL] [Abstract][Full Text] [Related]
12. LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson's disease.
Nguyen M; Krainc D
Proc Natl Acad Sci U S A; 2018 May; 115(21):5576-5581. PubMed ID: 29735704
[TBL] [Abstract][Full Text] [Related]
13. Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release.
Volta M; Cataldi S; Beccano-Kelly D; Munsie L; Tatarnikov I; Chou P; Bergeron S; Mitchell E; Lim R; Khinda J; Lloret A; Bennett CF; Paradiso C; Morari M; Farrer MJ; Milnerwood AJ
Parkinsonism Relat Disord; 2015 Oct; 21(10):1156-63. PubMed ID: 26282470
[TBL] [Abstract][Full Text] [Related]
14. Genetic reduction of mitochondrial complex I function does not lead to loss of dopamine neurons in vivo.
Kim HW; Choi WS; Sorscher N; Park HJ; Tronche F; Palmiter RD; Xia Z
Neurobiol Aging; 2015 Sep; 36(9):2617-27. PubMed ID: 26070241
[TBL] [Abstract][Full Text] [Related]
15. Role of LRRK2 in the regulation of dopamine receptor trafficking.
Rassu M; Del Giudice MG; Sanna S; Taymans JM; Morari M; Brugnoli A; Frassineti M; Masala A; Esposito S; Galioto M; Valle C; Carri MT; Biosa A; Greggio E; Crosio C; Iaccarino C
PLoS One; 2017; 12(6):e0179082. PubMed ID: 28582422
[TBL] [Abstract][Full Text] [Related]
16. LRRK2 Kinase Inhibitor Rejuvenates Oxidative Stress-Induced Cellular Senescence in Neuronal Cells.
Ho DH; Nam D; Seo MK; Park SW; Seol W; Son I
Oxid Med Cell Longev; 2021; 2021():9969842. PubMed ID: 34306319
[TBL] [Abstract][Full Text] [Related]
17. Vacuolar protein sorting 35 (Vps35) rescues locomotor deficits and shortened lifespan in Drosophila expressing a Parkinson's disease mutant of Leucine-Rich Repeat Kinase 2 (LRRK2).
Linhart R; Wong SA; Cao J; Tran M; Huynh A; Ardrey C; Park JM; Hsu C; Taha S; Peterson R; Shea S; Kurian J; Venderova K
Mol Neurodegener; 2014 Jun; 9():23. PubMed ID: 24915984
[TBL] [Abstract][Full Text] [Related]
18. LRRK2(I2020T) functional genetic interactors that modify eye degeneration and dopaminergic cell loss in Drosophila.
Marcogliese PC; Abuaish S; Kabbach G; Abdel-Messih E; Seang S; Li G; Slack RS; Haque ME; Venderova K; Park DS
Hum Mol Genet; 2017 Apr; 26(7):1247-1257. PubMed ID: 28158614
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective Effect of the LRRK2 Kinase Inhibitor PF-06447475 in Human Nerve-Like Differentiated Cells Exposed to Oxidative Stress Stimuli: Implications for Parkinson's Disease.
Mendivil-Perez M; Velez-Pardo C; Jimenez-Del-Rio M
Neurochem Res; 2016 Oct; 41(10):2675-2692. PubMed ID: 27394417
[TBL] [Abstract][Full Text] [Related]
20. Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice.
Yue M; Hinkle KM; Davies P; Trushina E; Fiesel FC; Christenson TA; Schroeder AS; Zhang L; Bowles E; Behrouz B; Lincoln SJ; Beevers JE; Milnerwood AJ; Kurti A; McLean PJ; Fryer JD; Springer W; Dickson DW; Farrer MJ; Melrose HL
Neurobiol Dis; 2015 Jun; 78():172-95. PubMed ID: 25836420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
